Table 1.
Characteristics of 269 metastatic castration resistant prostate cancer (mCRPC) patients stratified according to treatment in first- or second-line mCRPC with 177-lutetium prostate-specific membrane antigen (Lu-PSMA) vs. androgen receptor pathway inhibitor (ARPI) or Lu-PSMA vs. docetaxel chemotherapy
| A | B | ||||||
|---|---|---|---|---|---|---|---|
| Characteristic | N | Overall N = 2691 |
Lu-PSMA, N = 29 (11%)a |
ARPI, N = 152 (57%)a |
p-valueb | Docetaxel, N = 88 (33%)a |
p-valueb |
| Age at metastatic disease, years | 256 | 71 (65, 77) | 74 (69, 79) | 72 (66, 77) | 0.055 | 68 (62, 73) | < 0.001 |
| Age at mCRPC, years | 167 | 72 (67, 79) | 76 (73, 83) | 74 (68, 79) | 0.083 | 69 (64, 75) | < 0.001 |
| PSA at mCRPC, ng/ml | 133 | 17 (6, 47) | 23 (9, 82) | 18 (5, 47) | 0.2 | 12 (4, 40) | 0.091 |
| Systemic treatment lines for mCRPC | 269 | 3 (2, 4) | 2 (1, 2) | 3 (2, 4) | < 0.001 | 3 (3, 5) | < 0.001 |
| Received cycles | 139 | 3 (2, 6) | 3 (2, 5) | 4 (2, 6) | 0.2 | ||
| PSA response, % | 26 | 23 (4, 62) | 20 (11, 30) | 17 (0, 90) | 0.9 | 41 (17, 62) | 0.3 |
| ECOG at mCRPC | 87 | 0.13 | 0.017 | ||||
| 0 | 40 (46%) | 4 (24%) | 17 (45%) | 19 (59%) | |||
| 1–2 | 47 (54%) | 13 (76%) | 21 (55%) | 13 (41%) | |||
| Cardiovascular disease | 171 | 64 (37%) | 9 (50%) | 33 (34%) | 0.2 | 22 (39%) | 0.4 |
| Gleason score 8–10 | 234 | 165 (71%) | 16 (62%) | 89 (69%) | 0.5 | 60 (76%) | 0.2 |
| Local therapy | 269 | 112 (42%) | 12 (41%) | 52 (34%) | 0.5 | 48 (55%) | 0.2 |
| De Novo metastatic disease | 259 | 140 (54%) | 15 (54%) | 86 (59%) | 0.6 | 39 (45%) | 0.4 |
| High volume mHSPC | 104 | 55 (53%) | 6 (67%) | 35 (54%) | 0.7 | 14 (47%) | 0.5 |
| Metastatic sites at mCRPC | 110 | 0.8 | 0.4 | ||||
| M1a | 13 (12%) | 2 (11%) | 5 (10%) | 6 (15%) | |||
| M1b | 91 (83%) | 15 (79%) | 42 (84%) | 34 (83%) | |||
| M1c | 6 (5.5%) | 2 (11%) | 3 (6.0%) | 1 (2.4%) | |||
| Pre-treatment | 269 | ||||||
| ARPI | 269 (100%) | 29 (100%) | 152 (100%) | 88 (100%) | |||
| Docetaxel | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |||
Abbreviations: PSA, Prostate-specific antigen; ECOG, Eastern Cooperative Oncology group; mHSPC, metastatic hormone-sensitive prostate cancer; ADT, Androgen deprivation therapy; nmHSPC, non-metastatic hormone-sensitive prostate cancer; m0CRPC, non-metastatic CRPC
aMedian (Q1, Q3); n (%);2 Kruskal-Wallis rank sum test; Fisher’s exact test; Pearson’s Chi-square test
bKruskal-Wallis rank sum test; Fisher’s exact test; Pearson’s Chi-square test